A5041249662- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Lung Cancer Treatments and Mutations
- Cutaneous lymphoproliferative disorders research
- Ovarian cancer diagnosis and treatment
- Cancer therapeutics and mechanisms
- Neutropenia and Cancer Infections
- Renal Diseases and Glomerulopathies
- Galectins and Cancer Biology
- Chronic Myeloid Leukemia Treatments
- CNS Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Forensic Toxicology and Drug Analysis
- Dermatological and COVID-19 studies
- Histone Deacetylase Inhibitors Research
- Cancer-related cognitive impairment studies
- Autoimmune and Inflammatory Disorders
- Autoimmune and Inflammatory Disorders Research
- Sarcoma Diagnosis and Treatment
Ottawa Hospital
2013-2023
University of Ottawa
2006-2023
Ottawa Hospital Research Institute
2012-2016
Emory University
2015
Georgetown University
2005
Leukemia & Lymphoma Society of Canada
2004
Ottawa Public Health
2004
University of Michigan
1998
Cancer Research Center
1993
Fred Hutch Cancer Center
1993
The BRIGHT study ( ClinicalTrials.gov identifier: NCT00877006) was initiated to compare the efficacy and safety of bendamustine plus rituximab (BR) with either cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) or (R-CVP) for treatment-naive patients indolent non-Hodgkin lymphoma mantle-cell lymphoma. This publication provides long-term follow-up data.Patients were monitored a minimum 5 years after completion treatment time-to-event end points progression-free survival (PFS),...
BACKGROUND Patients with T‐cell lymphomas face a poorer prognosis compared patients B‐cell lymphomas. New therapeutic approaches need to be developed improve outcomes for these patients. METHODS Forty recurrent and refractory other than mycosis fungoides untreated lymphoma who were not candidates combination chemotherapy prescribed oral lenalidomide at dose of 25 mg daily on days 1 21 each 28‐day cycle, standardized reductions toxicity. The primary endpoint was overall response rate (ORR),...
MGCD0103, an orally available class I histone deacetylase (HDAC) inhibitor, was examined for pre-clinical activity in chronic lymphocytic leukaemia (CLL). A phase II clinical trial performed, starting at a dose of 85 mg/d, three times per week. Dose escalation to 110 mg or the addition rituximab permitted patients without response after two more cycles. MGCD0103 demonstrated against CLL cells with LC(50) (concentration lethal 50%) 0.23 micromol/l and increased acetylation HDAC specific...
Abstract BACKGROUND: Novel therapies are needed to improve outcomes in T‐cell lymphomas. The authors report the interim results of a prospective multicenter trial evaluating lenalidomide METHODS: Patients with recurrent and refractory lymphomas other than mycosis fungoides untreated patients ineligible for combination chemotherapy were prescribed oral (25 mg daily) on Days 1 21 each 28‐day cycle until disease progression, death, or unacceptable toxicity. primary endpoint was overall response...
We report an analysis of minimal residual/detectable disease (MRD) as a predictor outcome in previously untreated patients with follicular lymphoma (FL) from the randomized, multicenter GALLIUM (ClinicalTrials.gov identifier: NCT01332968) trial.
One of the most common decisions physicians face is deciding which therapeutic intervention appropriate for their patients. In recent years much emphasis has been placed on making clinical that are based evidence from medical literature. Despite incorporation evidence-based medicine into undergraduate curriculum and postgraduate training programs, there controversy regarding proportion interventions supported by health care research.To investigate major at our institution justified published...
Renal impairment is associated with poor prognosis in myeloma. This analysis of the pivotal phase 3 FIRST trial examined impact renally adapted dosing lenalidomide and dexamethasone on outcomes patients different degrees renal impairment. Transplant-ineligible not requiring dialysis were randomized 1:1:1 to receive continuous until disease progression (n=535) or for 18 cycles (72 weeks; n=541), melphalan, prednisone, thalidomide 12 n=547). Follow-up ongoing. Patients grouped by baseline...
FK-506 was evaluated either alone or combined with methotrexate (MTX) for prevention of graft-versus-host disease (GVHD) in dogs given 9.2 Gy total body irradiation and dog leukocyte antigen-nonidentical unrelated marrow grafts. Studies autografts showed gut toxicity weight loss to be major side effects FK-506. There no hematopoietic In an initial allograft study, 5 were intramuscularly at 0.3 mg/kg/day from days 0 8 then orally 0.5 mg/kg/day. All died, 3 intussusception most likely due...
7500 Background: BRIGHT, a phase 3, open-label, noninferiority study comparing efficacy and safety of bendamustine plus rituximab (BR) vs cyclophosphamide, doxorubicin, vincristine prednisone (R-CHOP) or with (R-CVP) in treatment-naive patients (pts) indolent non-Hodgkin lymphoma (iNHL) mantle cell (MCL), showed that the complete response rate for first-line BR was statistically noninferior to R-CHOP/R-CVP ( Blood 2014). Pts were monitored ≥5 years (yr) assess overall effect controlled...
Prostatic mantle cell lymphoma (MCL) is a very rare entity with only 5 reported cases in the literature. We report case of coexisting MCL and prostate adenocarcinoma (PCa) an elderly male review morphologic features classic prostatic subtypes. Careful evaluation immunohistochemical findings positive CD5, CD20, cyclin D1 negative CD23 CD3 can guide us to diagnosis MCL. Given fact that transurethral resection done quite routinely, this paper draws attention manner which long standing bladder...
Despite the success of standard treatments in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), patients are often unable to tolerate aggressive regimens, they require effective alternatives. Bendamustine is a bifunctional alkylator with unique properties that significantly distinguish it from other agents its class. In untreated CLL, bendamustine has demonstrated rates response progression-free survival (PFS) superior those chlorambucil, an acceptable toxicity profile....
A uniquely indolent case of necrobiotic xanthogranuloma with bilateral, periorbital involvement was presented. This patient presented cutaneous eyelid lesions 20 years' duration. Although symptomless, the underwent testing for hematologic malignancy, which led to a diagnosis multiple myeloma. review literature revealed that this is longest interval between onset skin manifestations and systemic malignancy in rare disease.
Introduction: BRIGHT, a phase 3, open-label, noninferiority study comparing efficacy and safety of bendamustine plus rituximab (BR) vs cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) or with (R-CVP) in treatment-naive patients indolent non-Hodgkin lymphoma (iNHL) mantle cell (MCL), showed that the complete response rate for first-line BR was statistically noninferior to R-CHOP/R-CVP (Blood 2014;123:2944-52). Patients were monitored ≥5 years assess overall effect controlled...
6564 Background: Treanda (bendamustine HCl) (T), a novel DNA-alkylating cytotoxic agent, has been shown to be active in vitro against variety of alkylator-resistant cell lines. Moreover, T combination with the anti-CD20 monoclonal antibody rituximab (R), enhances tumor growth inhibition Daudi lymphoma xenograft models. We have extended these observations through 2 Phase II multi-center clinical trials (SDX-105–01 and SDX-105–02). Methods: The SDX-105–01 trial enrolled patients (pts) relapsed...